Compare GOCO & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOCO | HOTH |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 17.7M |
| IPO Year | 2020 | 2018 |
| Metric | GOCO | HOTH |
|---|---|---|
| Price | $1.13 | $0.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.75 | ★ $5.00 |
| AVG Volume (30 Days) | 52.3K | ★ 3.3M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $361,845,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $77.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.49 |
| 52 Week High | $9.50 | $2.12 |
| Indicator | GOCO | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 41.91 | 49.51 |
| Support Level | $1.00 | $0.49 |
| Resistance Level | $1.35 | $0.78 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 40.58 | 81.30 |
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions, so it can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. The proprietary technology platform integrates artificial intelligence and modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).